Please login to the form below

Not currently logged in
Email:
Password:

palbociclib

This page shows the latest palbociclib news and features for those working in and with pharma, biotech and healthcare.

Lilly gets EMA nod for Verzenio in breast cancer

Lilly gets EMA nod for Verzenio in breast cancer

The approved uses match the indications for Verzenio in the US, and take Lilly another step forward in its pursuit of CDK4/6 market leader Ibrance (palbociclib) from Pfizer - which grew

Latest news

More from news
Approximately 7 fully matching, plus 45 partially matching documents found.

Latest Intelligence

  • Engaging the digital healthcare professional Engaging the digital healthcare professional

    When NICE, the UK policymaker for health spending, rejected Pfizer’s breast cancer drug palbociclib for routine funding on the NHS in February, it tweeted the news and invited comments on ... Weeks later, following the NICE consultation period, the

  • Pharma deals during August 2013 Pharma deals during August 2013

    Palbociclib, which is the result of an early partnership with Pfizer and now being developed by Pfizer, is in phase III trials for advanced breast cancer and certain haematologic malignancies. ... If approved, Onyx will receive an 8 per cent royalty on

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Pharma and free medicines: a different perspective

    The cost of a full course of treatment with palbociclib is approximately £80, 000. ... Therefore, it will be interesting to see the final ruling of NICE on palbociclib.

  • Synergy Vision

    Pfizer have recently announced that they will provide the breast cancer drug, palbociclib, free of charge to patients.

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics